US Patent 8426428 EGFR kinase knockdown via electrophilically enhanced inhibitors
Patent 8426428 was granted and assigned to Principia Biopharma Inc. on April, 2013 by the United States Patent and Trademark Office.
Currently, there are no issues on this topic.
Find more entities like US Patent 8426428 EGFR kinase knockdown via electrophilically enhanced inhibitors
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
